NMS Labs
3701 Welsh Road, PO Box 433A, Willow Grove, PA 19090-0437
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, DABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Demo Report

Report Issued 09/09/2011 13:57
Last Report Issued 06/06/2011 07:31

88888
Clinical Dummy reports
Attn: IT Department
3701 Welsh Road
Willow Grove, PA 19090

Patient Name 1445SP-POS
Patient ID 1445SP-POS
Chain 11001252
Age Not Given **Gender** Not Given

Workorder 11001252

Received 06/06/2011 07:20

Sample ID 11001252-001
Matrix Serum or Plasma
Patient Name 1445SP-POS
Patient ID 1445SP-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
1445SP Dabigatran, Serum/Plasma				
Analysis by High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)				
Dabigatran	20	ng/mL	10	
Synonym(s): Pradaxa®				
Peak plasma concentrations of free dabigatran following three times daily dosing with dabigatran etexilate for seven days (n=8) were as follows: 50 mg (150 mg per day): 42 ng/mL (42% CV) 100 mg (300 mg per day): 130 ng/mL (46% CV)				